457 related articles for article (PubMed ID: 24848709)
1. Therapeutic potential of Dickkopf-1 in wild-type BRAF papillary thyroid cancer via regulation of β-catenin/E-cadherin signaling.
Cho SW; Kim YA; Sun HJ; Ahn HY; Lee EK; Yi KH; Oh BC; Park DJ; Cho BY; Park YJ
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1641-9. PubMed ID: 24848709
[TBL] [Abstract][Full Text] [Related]
2. Dickkopf-1 inhibits thyroid cancer cell survival and migration through regulation of β-catenin/E-cadherin signaling.
Cho SW; Lee EJ; Kim H; Kim SH; Ahn HY; Kim YA; Yi KH; Park DJ; Shin CS; Ahn SH; Cho BY; Park YJ
Mol Cell Endocrinol; 2013 Feb; 366(1):90-8. PubMed ID: 23261982
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
[TBL] [Abstract][Full Text] [Related]
5. Sulindac reverses aberrant expression and localization of beta-catenin in papillary thyroid cancer cells with the BRAFV600E mutation.
Cho NL; Lin CI; Whang EE; Carothers AM; Moore FD; Ruan DT
Thyroid; 2010 Jun; 20(6):615-22. PubMed ID: 20470206
[TBL] [Abstract][Full Text] [Related]
6. β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in
Zou M; Al-Yahya S; Al-Alwan M; BinEssa HA; Khabar KSA; Almohanna F; Assiri AM; Altaweel A; Qattan A; Meyer BF; Alzahrani AS; Shi Y
Front Immunol; 2023; 14():1171816. PubMed ID: 37483610
[TBL] [Abstract][Full Text] [Related]
7. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
8. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
9. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
Fisher KE; Jani JC; Fisher SB; Foulks C; Hill CE; Weber CJ; Cohen C; Sharma J
J Surg Res; 2013 Nov; 185(1):217-24. PubMed ID: 23746767
[TBL] [Abstract][Full Text] [Related]
11. Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer.
Dultz LA; Dhar S; Ogilvie JB; Heller KS; Bar-Sagi D; Patel KN
Surgery; 2013 Dec; 154(6):1239-44; discussion 1244-5. PubMed ID: 24094449
[TBL] [Abstract][Full Text] [Related]
12. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
Kim SW; Kim HK; Lee JI; Jang HW; Choe JH; Kim JH; Kim JS; Hur KY; Kim JH; Chung JH
Endocr Res; 2013; 38(2):89-97. PubMed ID: 23544999
[TBL] [Abstract][Full Text] [Related]
13. LGR5 is associated with tumor aggressiveness in papillary thyroid cancer.
Michelotti G; Jiang X; Sosa JA; Diehl AM; Henderson BB
Oncotarget; 2015 Oct; 6(33):34549-60. PubMed ID: 26416247
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of TRIM44 inhibits the proliferation and invasion in papillary thyroid cancer cells through suppressing the Wnt/β-catenin signaling pathway.
Zhou Z; Liu Y; Ma M; Chang L
Biomed Pharmacother; 2017 Dec; 96():98-103. PubMed ID: 28965013
[TBL] [Abstract][Full Text] [Related]
15. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
Ulisse S; Baldini E; Sorrenti S; Barollo S; Prinzi N; Catania A; Nesca A; Gnessi L; Pelizzo MR; Mian C; De Vito C; Calvanese A; Palermo S; Persechino S; De Antoni E; D'Armiento M
Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
[TBL] [Abstract][Full Text] [Related]
16. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
17. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
18. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
[TBL] [Abstract][Full Text] [Related]
19. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]